U.S. markets closed

Kindred Biosciences, Inc. (KIN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9300+0.4800 (+10.79%)
At close: 4:00PM EST
Sign in to post a message.
  • B
    Bill
    What's with all the volume on the upside today?
  • S
    S
    I seem to miss everything this company is doing. When did Kindred give Dechra the exclusive marketing rights to Zimeta? I guess it is not s big deal since this drug's sales numbers were worse than anything I could have predicted. I don't understand how they got this drug this wrong.
  • D
    Dave
    Kindred Biosciences stock price $10.25 ( from Alliance Global Partners 12-1-20)
  • S
    S
    What is next for KIN?
  • M
    Michael
    Is the production agreement with $VXRT the only thing that will move this stock forward ? Depending on successful trial at Vaxart ?
  • S
    S
    So, I have greatly increased my position in this company while the price had been below $4. Since I am very aware that there is upside potential in this stock could someone show any possible downside risks.
    Thanks.
  • S
    S
    So the anti-TNFα antibody result were positive. No market reaction. Maybe because the company will not be able to do anything with this drug any time soon. Can we assume that the Miretaz royalties + latest partnership agreement (plus other manufacturing agreements) just aren't enough to add an additional drug candidate?
  • S
    S
    So is this what the agreement says means in plain language?
    "an upfront payment of $500,000" [they get that now]?
    "development milestone payments of up to $16 million upon achievement of certain development [as they complete the different studies], regulatory [drug get approved] and manufacturing targets [when their factory is up and running producing the drug],
    "sales milestones in an aggregate amount of up to $94 million payable throughout the term of the agreement. Furthermore, royalty payments are to range from the low to high teens. [they $94 million as they hit certain sales milestones and the they get the additional low to high teens of total sales?].
    Furthermore, "Elanco will conduct the necessary regulatory activities to achieve approvals in Europe and other key international markets." [Elanco will pay for all the expenses of getting this drug approved outside of the US?]
    Do I have that right?
  • A
    AVA
    HC Wainwright new target price $9 today. 5 star analyst on this stock according to ETRADE
  • S
    S
    Congratulations everyone.
    @Steve L. How do you feel about this agreement?
  • S
    S
    @Steve L you seem to be the the most knowledgeable here about KIN and the veterinarian drug space. At the recent Stifel Virtual Healthcare Conference Richard Chin said that they felt they needed to make a pivot and start to partner with large veterinarian drug companies. There first reason was that they could not effectively bring a drug to market themselves. Secondly, and maybe more importantly, Richard said that they made a pivot because partners were willing to pay more than they had expected. The second issue is the one that I am curious about. For Mirataz KIN received an upfront royalty payment of $43 m and then low teens royalty payments. There are advantages and disadvantage of partnerships. With partnerships there will be both but lower revenue and lower costs. I wonder how you feel about KIN's revenue potential judging from what we have seen so far ($43m + low teens royalty).
  • j
    joe
    THE FART SUPPORTS KINDRED
  • S
    S
    I think they told us that KIND-030 might be delayed but now it is official. "notice that due to a delay in receiving appropriate vendor reagent material, completion of the upcoming pivotal efficacy study for KIND-030, a monoclonal antibody targeting canine parvovirus, is now expected in the first quarter of 2021"
  • D
    Dave
    Check out the insider selling of one of their directors. What kind of confidence does that show in the company. Look at form 4

    https://old.nasdaq.com/symbol/kin/sec-filings
  • S
    S
    What is the next news that we should be waiting for?
  • S
    S
    So my last post was a bit negative.
    We can find positives if we look. The company does seem to be able to execute. They delivered on their promise of cutting costs (ahead of time I believe). They are moving forward with their pipeline at a good pace. The royalty payments were not bad (considering the agreement only gives them a high single digit royalty).
    What is the next positive that we can look forward to?
  • C
    Chuck
    Big time agreement!
  • S
    S
    So, what did we learn from Q3 report? The entire equine does not seem to be worth much.
    We can expect the pipeline to be delayed. Anything else?
    I have have been patient. I have not given up yet but if I am honest I am surprised by how little KIN have to show for the last 5 years.
  • S
    S
    Decided to double my position last week.
  • S
    S
    Was anyone able to get access to the A.G.P. Virtual Healthcare Symposium on November 19. There is no link on the website.